Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

E Zanon, S Pasca, S Siragusa, M Napolitano… - Thrombosis …, 2019 - Elsevier
Background Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …
被引用次数：14 相关文章

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry.

E Zanon, S Pasca, S Siragusa, M Napolitano… - Thrombosis …, 2018 - europepmc.org
BACKGROUND: Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

E Zanon, S Pasca, S Siragusa, M Napolitano… - THROMBOSIS …, 2019 - iris.unipa.it
Background: Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

E Zanon, S Pasca, S Siragusa… - THROMBOSIS …, 2019 - research.unipd.it
Background: Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

E Zanon, S Pasca, S Siragusa… - Thrombosis …, 2019 - thrombosisresearch.com
Background Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

E Zanon, S Pasca, S Siragusa… - Thrombosis …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …